JAK Inhibitors in Alopecia Areata: A Case for Persistence?
Oral Janus kinase inhibitors (JAKi) have emerged as a promising treatment for severe alopecia areata, with FDA-approved options now available. But what happens when initial therapy doesn’t deliver the expected results?
A new case report explores the long-term use of JAK inhibitors and what may influence treatment success in patients with refractory disease. The findings raise important considerations about treatment duration and intra-class switching—key factors that could impact clinical decision-making.
Could an adjusted approach to JAKi therapy improve patient outcomes?
